Thiamine Deficiency and Neurological Symptoms in Patients with Hematological Cancer Receiving Chemotherapy: A Retrospective Analysis

Yohei Iimura1  Shohei Andoh2  Toyotaka Kawamata2  Aki Sato2  Kazuaki Yokoyama2  Yoichi Imai2  Arinobu Tojo2  Masanori Nojima3  Munetoshi Sugiura4  Seiichiro Kuroda1

1Department of Pharmacy, The IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
2Department of Hematology/Oncology, The Institute of Medical Science Hospital, The University of Tokyo, Tokyo, Japan
3Center for Translational Research, The Institute of Medical Science Hospital, The University of Tokyo, Tokyo, Japan
4Department of Drug Safety and Risk Management, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Hachioji, Japan

Abstract

Objectives Patients with hematological cancer receiving chemotherapy have a high risk of thiamine deficiency due to accelerated thiamine usage by tumor cells. Mild or severe thiamine deficiency can lead to varying degrees of neurological symptoms. We evaluated the relationship between thiamine deficiency and neurological symptoms, including mild or nonspecific symptoms, and the influence of chemotherapy on thiamine serum levels in patients with hematological cancer receiving chemotherapy.

Materials and Methods We retrospectively identified 42 patients diagnosed with hematological cancer at our hospital, using electronic medical records collected from March 2019 to March 2020. We evaluated the risk factors associated with neurological symptoms (mild-to-severe cognitive impairment, attention impairment, and mood or emotional disorder), the relationship between the presence of neurological symptoms and thiamine serum levels, and changes in thiamine serum levels after chemotherapy.

Results Thiamine deficiency was significantly associated with neurological symptoms. The thiamine serum levels in the group with neurological symptoms were significantly lower than those in the group without neurological symptoms. The Wilcoxon rank-sum test showed that thiamine serum levels after chemotherapy were significantly lower than those before administration of chemotherapy.

Conclusion Thiamine serum levels in patients with hematological cancer may be used as a reference to maintain neurological status during chemotherapy.

Keywords
- thiamine deficiency
- hematological cancer
- chemotherapy
- neurological symptoms

DOI https://doi.org/10.1055/s-0041-1735825.
ISSN 0976-3147.

© 2021. Association for Helping Neurosurgical Sick People. All rights reserved.
This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd., A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
Introduction

Thiamine deficiency induced by tumor cells, gastrointestinal disorders, and chemotherapy can develop in patients with cancer.\textsuperscript{1,2} In particular, thiamine deficiency can be more likely to occur in patients with hematological cancer, because of accelerated thiamine usage by tumor cells.\textsuperscript{4-8} Thiamine deficiency may lead to memory disorders,\textsuperscript{7} cognitive impairment,\textsuperscript{8-10} and mood disorders or depression.\textsuperscript{11-13} Most reports on thiamine deficiency have suggested a relationship between thiamine deficiency and severe neuropsychiatric disorders (e.g., Wernicke–Korsakoff syndrome\textsuperscript{10-13}) in patients with various diseases. However, nonspecific symptoms such as weariness, headache, anorexia, sleep and mood disorders, poor coordination, and cognitive impairment related to thiamine deficiency, have been reported.\textsuperscript{14} Thiamine-related neurological symptoms may not be limited to only severe disease but also in nonspecific neurological symptoms caused by a mild deficiency in thiamine levels, and their symptoms can vary. However, the reports have been very limited and require further investigation.

Hematological and gastric cancers are the most common cancer types that lead to thiamine deficiency, because of decreased absorption and accelerated usage of thiamine.\textsuperscript{1,3} Although the number of patients was small, previous studies have shown that even mild deficiency in thiamine serum levels was associated with neurological symptoms (cognitive impairment, attention decline, and mood disorder) in patients with gastrointestinal cancer.\textsuperscript{17-19} However, there have been no reports on this in patients with hematological cancer. The relationship between mild-to-severe thiamine deficiency and neurological symptoms, including mild or nonspecific symptoms in patients with hematological cancer receiving chemotherapy, should be evaluated.

Furthermore, thiamine serum levels are not regularly evaluated in most hospitals.\textsuperscript{20} In clinical practice, thiamine serum levels are evaluated only for patients who develop severe neurological symptoms, suspected to be caused by thiamine deficiency. Additionally, serum thiamine is often analyzed at an outside laboratory, and results are returned after a few days. Hence, thiamine deficiency is often overlooked in practice. In fact, 80% of cases of Wernicke–Korsakoff syndrome were diagnosed after death.\textsuperscript{14}

However, thiamine deficiency is not uncommon in patients with cancer.\textsuperscript{1,3} Cognitive impairment leads to a lack of adherence and self-care for chemotherapy-related adverse events,\textsuperscript{21} and mood or emotional disturbance and depression are injurious for cancer therapy. These previous studies suggested a relationship between neurological symptoms related to thiamine deficiency and absence of thiamine serum levels evaluation in patients with cancer. We believe that thiamine deficiency can develop more frequently and may lead to mild-to-severe neurological symptoms. Even if the neurological symptoms induced by thiamine deficiency were mild or nonspecific, these symptoms can be injurious for patients with hematological cancer receiving chemotherapy. Hence, an evaluation of thiamine serum levels at an early stage may be important.

The present study aimed at evaluating the relationship between thiamine deficiency and neurological symptoms in patients with hematological cancer receiving chemotherapy. In addition, we investigated changes in thiamine serum levels before and after administration of chemotherapy in chemotherapy-naïve patients, as a subset analysis, to evaluate the influence of chemotherapy on thiamine serum levels.

Materials and Methods

Study Design

This was a single-center, retrospective observational study. We enrolled patients diagnosed with hematological cancer who were admitted to the IMSUT Hospital, The Institute of Medical Science, The University of Tokyo (hereafter, our hospital) between March 2019 and March 2020. We only included patients with hematological cancer who had their thiamine serum levels measured. We performed a risk factor analysis in relation to neurological symptoms, including mild or nonspecific symptoms (cognitive impairment, attention impairment, and mood or emotional disorder). Thiamine serum levels were measured at the start of chemotherapy or from the middle course of chemotherapy and were continuously measured during the chemotherapy.

Regarding the definition of the presence of neurological symptoms, patients who had neurological symptoms, such as cognitive impairment, attention impairment, and mood disorder on their electronic medical records in which an incident report was filed or where treatment was interfered with, were considered to have neurological symptoms. The presence of neurological symptoms was recorded from episodes up to 7 days before measurements of thiamine serum levels. Furthermore, we investigated the relationship between serum thiamine levels and the occurrence of neurological symptoms. As a subgroup analysis, we evaluated the changes in thiamine serum levels before and after the administration of chemotherapy in chemotherapy-naïve patients. The cohort laboratory test results and clinical data were retrospectively collected from electronic medical records. We excluded patients with brain metastasis—those with a medical history of cerebrovascular accident or depression, or patients who were administered thiamine-containing agents prior to the start of chemotherapy. In accordance with the Japanese reference guidelines, serum thiamine levels < 24 ng/mL were considered to be low.

Statistical Analysis

We performed a multivariate analysis (logistic regression, including factors with $p < 0.05$ in the univariate analysis) to investigate the risk factors for neurological symptoms, including mild or nonspecific symptoms. The number of covariates included in the logistic model was limited due to the small number of events. In addition, we performed a comparative analysis using the Mann–Whitney U test of the thiamine serum levels between the patient groups with and without neurological symptoms, including mild or nonspecific symptoms. To evaluate thiamine serum levels before or after chemotherapy administration, the Wilcoxon
rank-sum test was performed. The threshold for significance was set at \( p < 0.05 \). Statistical analyses were performed using EZR version 1.36 software (Saitama Medical Center, Jichi Medical University; Saitama, Japan).

**Results**

**Patient Characteristics**
A total of 42 patients were enrolled in this retrospective study. No patient was excluded because of the exclusion criteria. The median age was 65 years, and the sex ratio was approximately 1:1. The most common type of cancer was non-Hodgkin lymphoma (29%). The division between lymphoma, myeloma, leukemia, and other types of hematological cancer was 33%, 19%, 36%, and 12%, respectively. Moreover, 98% of the patients did not have a history of alcohol consumption. According to the Eastern Cooperative Oncology Group (ECOG) Performance Status, all patients had a score of 0 (fully active, able to carry on all predisease performance without restriction). Although the baseline median laboratory values did not significantly deviate from the reference values, thiamine serum levels were lower than the reference values, and some patients were affected with hepatic impairment, renal impairment, and high levels of inflammation. Some patients had abnormal laboratory values of the blood cell system because of the disease (Table 1).

**Multivariate Analysis (Including Factors with \( p < 0.05 \) in the Univariate Analysis)**
A logistic regression analysis revealed that a decrease in thiamine serum levels was the only statistically significant factor associated with neurological symptoms, including mild or nonspecific symptoms (\( p = 0.001 \), odds ratio = 0.015, 95% CI: 0.001 – 0.180). The explanatory variables selected were \( p < 0.05 \) in the univariate and multivariate analyses. Since age > 65 years (\( p = 0.90 \)), serum albumin \( \leq 4.1 \) mg/dL (\( p = 0.81 \)), serum vitamin B12 level < 180 pg/mL (\( p = 0.11 \)), serum folic acid level < 4.0 ng/mL (\( p = 0.06 \)), serum sodium level < 139 mEq/L (\( p = 0.13 \)), and sex (\( p = 0.85 \)) all had a \( p > 0.05 \) in the univariate analysis, they were not included in the explanatory variables in the multivariate analysis (Table 2).

**Relationship between the Presence of Neurological Symptoms, Including Mild or Nonspecific Symptoms and Thiamine Serum Levels**
The relationship between the presence of neurological symptoms and thiamine serum levels is shown in Fig. 1. The group with neurological symptoms had significantly lower serum thiamine levels (19.5 ± 5.4 ng/mL) than the group without neurological symptoms (31.9 ± 14.2 ng/mL, Mann–Whitney U test, \( p = 0.001 \)) (Fig. 1).

**Changes in Thiamine Serum Levels after Chemotherapy**
Subanalysis was performed in chemotherapy-naive patients. After the administration of chemotherapy, thiamine serum levels gradually declined, with the lowest levels at 5 to 8 weeks (23.5 ± 7.6 ng/mL, \( p = 0.035 \) vs. 0-week, Wilcoxon rank-sum test) (Fig. 2).

**Discussion**
This study investigated the relationship between mild-to-severe thiamine deficiency and neurological symptoms, including mild or nonspecific symptoms and changes in thiamine serum levels before and after administration of chemotherapy in patients with hematological cancer. The results showed that a decrease in thiamine serum levels was associated with neurological symptoms. Regarding the relationship between the presence of neurological symptoms and thiamine serum levels, the thiamine serum levels in the group with neurological symptoms were significantly lower than those in the group without neurological symptoms. In addition, thiamine serum levels declined significantly after administration of chemotherapy. None of the patients were suspected to have neurological disorders induced by electrolyte abnormalities, dehydration, and anemia, because the patients’ laboratory data during the study period were normal.

Previous studies have shown that thiamine deficiency is related to various neurological symptoms. However, thiamine-related neurological symptoms do not all present as serious symptoms, and mild or nonspecific symptoms may occur. If the patients are not treated for mild or subclinical thiamine deficiency, severe neurological symptoms may develop, which can be life-threatening. Although almost all reports have suggested an association between thiamine deficiency and severe neurological symptoms (for example, Wernicke–Korsakoff syndrome or depression), few reports have reported a relationship between thiamine deficiency, including mild deficiency, and neurological symptoms, including mild or nonspecific symptoms. Mechanisms involved in developing mild or nonspecific neurological symptoms, induced by mild thiamine deficiency, can be the same as those for severe neurological symptoms induced by severe thiamine deficiency. In particular, studies are required to examine the influence of gastrointestinal cancer and hematological cancer as risk factors for thiamine deficiency. Previous studies have shown that mild deficiency in thiamine serum levels was associated with neurological symptoms (cognitive impairment, attention decline, and mood disorder) in patients with gastrointestinal cancer. However, similar studies with patients with hematological cancer are required.

In cells, thiamine is a coenzyme for dehydrogenation in the glucose/amino acid metabolism pathway and plays an essential role in energy metabolism. A lack of thiamine leads to failure of the Krebs cycle. The accumulation of ketones in the body and the production of free radicals by the above mechanisms can adversely affect neurons in the brain. Because of their high-cell metabolism, patients with hematological cancer are likely to have rapid progress of the above mechanisms than patients with other cancer types. Therefore, patients with hematological cancer may have a high risk of thiamine deficiency.
### Table 1 Background of patients

| Median age, years (range) | 65 (20–83) |
|--------------------------|------------|
| Gender (male), n (%)     | 23 (55)    |
| Cancer type, n (%)       |            |
| Non-Hodgkin lymphoma     | 12 (29)    |
| Hodgkin lymphoma         | 2 (4.8)    |
| Multiple Myeloma         | 8 (20)     |
| Adult T-cell leukemia    | 7 (17)     |
| Acute myeloid leukemia   | 5 (12)     |
| Acute lymphocytic leukemia | 1 (2.4) |
| Chronic myelogenous leukemia | 2 (4.8) |
| Myelodysplastic syndromes | 1 (2.4) |
| Langerhans cell histiocytosis | 4 (9.5) |
| Drinking history (no), n (%) | 41 (98) |
| ECOG performance status, n (%) | 42 (100) |
| 0 (%)                    | 0 (0)      |
| 1 (%)                    | 0 (0)      |
| 2 (%)                    | 0 (0)      |
| Body mass index (kg/m²)  | 23.3 (15.8–28.7) |

### Laboratory parameter

| Aspartate aminotransferase (IU/L) | 23.5 (10–434) |
|-----------------------------------|---------------|
| Alanine aminotransferase (IU/L)   | 17.5 (6–87)   |
| Total bilirubin (mg/dl)           | 0.5 (0.2–1.5) |
| Serum creatinine (mg/dl)          | 0.78 (0.42–1.66) |
| White blood cell count (10^2/μL) | 36.6 (6.6–357.2) |
| Red blood cell count (10^4/μL)    | 352 (208–560) |
| Hemoglobin concentration (g/dL)   | 10.5 (6.5–17.0) |
| Serum albumin (g/dL)              | 3.6 (1.9–4.4) |
| Serum total protein (g/dL)        | 6.7 (4.9–11.7) |
| C-reactive protein (mg/dL)        | 0.29 (0.01–22.28) |
| Serum vitamin B₁₂ level (pg/mL)   | – (92 – >1500) |
| Serum folic acid level (ng/mL)    | – (1.7 – >22) |
| Serum thiamine level (ng/mL)      | 22 (11–96)    |
| History of pretreatment, n (%)    | 24 (57.1)     |
| Neurological symptoms (yes), n (%)|            |
| Cognitive impairment (%)          | 2 (4.8)       |
| Attention decline (%)             | 11 (26)       |
| Mood disorder (%)                 | 13 (31)       |

Abbreviation: ECOG, Eastern Cooperative Oncology Group.

### Table 2 Multivariate analysis (including factors with \( p < 0.05 \) in univariate analysis)

|                | 95% CI for OR |
|----------------|---------------|
| p-Value        | Lower         | Upper         |
| Serum thiamine (< 24 ng/mL) | 0.001 | 0.015 | 0.001 | 0.180 |
| Serum calcium (< 8.8 mg/dL)   | 0.156 | 3.830 | 0.599 | 24.50 |

Abbreviations: CI, confidence interval; OR, odds ratio.

Note: Factors with \( p < 0.05 \) in the univariate analysis were used as explanatory variables to perform multivariate analysis.
As expected, the logistic regression analysis showed that the decrease in thiamine serum levels was a statistically significant factor associated with neurological symptoms, including mild or nonspecific symptoms in this study. Other factors may have been associated with neurological symptoms: (1) serum vitamin B12 level and serum folic acid level can be related to neurological symptoms, (2) abnormalities in serum calcium and sodium levels can be associated with various neurological symptoms, (3) women are more likely to develop depressive symptoms compared with males, and (4) elderly people tend to have a lower cognitive function. However, these factors were not detected as significant factors; consequently, only the decrease in thiamine serum levels was considered to be a factor associated with neurological symptoms in this study. This result shows a strong correlation between serum thiamine levels and neurological symptoms in patients with hematological cancer receiving chemotherapy. In addition, the thiamine serum levels in the group with neurological symptoms were significantly lower than those in the group without neurological symptoms. The results of our study were concordant with those of a previous study on the relationship between severe neurological symptoms and thiamine deficiency. Regarding the changes in thiamine serum levels before and after the administration of chemotherapy, increased thiamine consumption in tumor cells and chemotherapy may further increase thiamine consumption as a result of enhanced cellular metabolism.

This study showed that neurological symptoms, including mild or nonspecific symptoms, were associated with thiamine deficiency in patients with hematological cancer receiving chemotherapy. Before progression to severe condition, mild or nonspecific symptoms associated with mild thiamine deficiency may develop. If thiamine serum levels are not evaluated, these mild symptoms may progress to more serious conditions. In patients with hematological cancer, thiamine deficiency may develop in the early stage. Therefore, based on these results, we suggest that evaluating thiamine serum levels in patients with early-stage hematological cancer may be important to better maintain...
neurological status during the therapy period. However, because some patients had subclinical thiamine deficiency, the presence of thiamine deficiency did not necessarily mean that they would develop neurological symptoms, and thiamine serum levels should be taken as one of the reference values.

**Limitations**

Several limitations of this study should be acknowledged. The limitations of the present study are as follows: (1) The number of cases is limited, which decreases the statistical power of the logistic regression analysis. (2) Assessments of cognitive decline, mood, or emotional disorder by objective scoring could not be performed. (3) We did not evaluate brain imaging findings (CT and MRI scans). (4) Further long-term investigations on the differences in thiamine deficiency according to anticancer drug types are warranted. (5) The analysis of neurological adverse events was limited to cognitive impairment, attention decline, and mood or emotional disorder, while we did not examine other neurological adverse events such as peripheral nerve disorders. Further studies with a larger number of cases are required. (6) In this study, we evaluated patients with good general status, but the same analysis should be conducted in patients with poor performance status in the future.

**Conclusions**

In summary, we performed a retrospective observational study to evaluate the relationship between neurological symptoms, including mild or nonspecific symptoms, and thiamine deficiency in patients with hematological cancer receiving chemotherapy. Neurological symptoms were associated with thiamine deficiency, and patients with neurological symptoms had lower serum thiamine levels.

**Ethical Approval**

This study was performed with the approval of our hospital's ethics committee (approval number: 30-83-A0306). Because of the anonymous nature of the data, the requirement for informed consent was waived.

**Authors’ Contributions**

Y.I. conceived the presented idea. S.A., T.K., A.S., M.S., and S.K. developed the theory. All authors discussed the results and contributed to the final article.

**Funding**

None.

**Conflict of Interests**

None declared.

**Acknowledgment**

The originality regarding the association between thiamine deficiency and neurological symptoms was first reported by Dr. Takeo Yasu. The authors are grateful to Dr. Yasu for suggesting the topic of this article.

**References**

1. Seligmann H, Levi R, Konjin AM, Prokoceimer M. Thiamine deficiency in patients with B-chronic lymphocytic leukemia: a pilot study. Postgrad Med J 2001;77(911):582–585.
2. Kim H-I, Hyung WJ, Song KJ, Choi SH, Kim C-B, Noh SH. Oral vitamin B12 replacement: an effective treatment for vitamin B12 deficiency after total gastrectomy in gastric cancer patients. Ann Surg Oncol 2011;18(13):3711–3717.
3. Aksoy M, Basu TK, Brient J, Dickerson JW. Thiamin status of patients treated with drug combinations containing 5-fluorouracil. Eur J Cancer 1980;16(08):1041–1045.
4. van Zaanen HC, van der Leelie J. Thiamine deficiency in hematologic malignant tumors. Cancer 1992;69(07):1710–1713.
5. Isenberg-Grzedzka E, Kutner HE, Nicolson SE. Wernicke-Korsakoff syndrome: under-recognized and under-treated. Psychosomatics 2012;53(06):507–516.
6. Boniol S, Boyd M, Koreth R, Burton GV. Wernicke encephalopathy complicating lymphoma therapy: case report and literature review. South Med J 2007;100(07):717–719.
7. Harper C. The neuropathology of alcohol-related brain damage. Alcohol 2009;44(02):136–140.
8. Scalzo SJ, Bowden SC, Ambrose ML, Whelan G, Cook MJ, Wernicke-Korsakoff syndrome not related to alcohol use: a systematic review. J Neurol Neurosurg Psychiatry 2015;86(12):1362–1368.
9. Zhao N, Zhong C, Wang Y, et al. Impaired hippocampal neurogenesis is involved in cognitive dysfunction induced by thiamine deficiency at early pre-pathological lesion stage. Neurobiol Dis 2008;29(02):176–185.
10. Isenberg-Grzedzka E, Alici Y, Hatzoglou V, Nelson C, Breithart W. Nonalcoholic thiamine-related encephalopathy (Wernicke-Korsakoff syndrome) among inpatients with cancer: a series of 18 cases. Psychosomatics 2016;57(01):71–81.
11. Benton D, Griffiths R, Haller J. Thiamine supplementation mood and cognitive functioning. Psychopharmacology (Berl) 1997;129(01):66–71.
12. Smidt LJ, Cremin FM, Grivetti LE, Clifford AJ. Influence of thiamin supplementation on the health and general well-being of an elderly Irish population with marginal thiamin deficiency. J Gerontol 1991;46(01):M16–M22.
13. Ghaleiha A, Davari H, Jahangard L, et al. Adjuvant thiamine improved standard treatment in patients with major depressive disorder: results from a randomized, double-blind, and placebo-controlled clinical trial. Eur Arch Psychiatry Clin Neurosci 2016;266(08):695–702.
14. Sechi G, Serra A. Wernicke’s encephalopathy: new clinical settings and recent advances in diagnosis and management. Lancet Neurol 2007;6(05):442–455.
15. Isenberg-Grzedzka E, Hsu AJ, Hatzoglou V, Nelson C, Breithart W. Palliative treatment of thiamine-related encephalopathy (Wernicke’s encephalopathy) in cancer: a case series and review of the literature. Palliat Support Care 2015;13(05):1241–1249.
16. Miller SM. Vitamins. In: Bishop ML, Duben-Engelkirk JL, Fody EP, eds. Clinical Chemistry: Principles, Procedures, Correlations. Philadelphia, New York: Lippincott; 1996:607–609.
17. Iimura Y, Yasu T, Momoi K, et al. Thiamine deficiency as a possible cofactor causing cognitive dysfunction in a patient with end-stage gastric cancer. Int J Clin Pharmacol Ther 2019;57(08):416–419.
18. Iimura Y, Kurokawa T, Nojima M, et al. Potential thiamine deficiency and neurological symptoms in patients receiving chemotherapy for gastrointestinal cancer. Int J Clin Pharmacol Ther 2020;58(03):139–145.
Yasu T, Iimura Y, Momo K, Kuroda S. Potential thiamine deficiency in elderly patients with gastrointestinal cancer undergoing chemotherapy. Int J Clin Pharmacol Ther 2020;58(03):174–176

Thomson AD, Marshall EJ, Guerrini I. Biomarkers for detecting thiamine deficiency—improving confidence and taking a comprehensive history are also important. Alcohol 2010;45(02):213

Hurria A, Cohen HJ, Extermann M. Geriatric Oncology Research in the Cooperative Groups: A Report of a SIOG Special Meeting. J Geriatr Oncol 2010;1(01):40–44

Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 2013;48(03):452–458

Gibson GE, Hirsch JA, Fonzetti P, Jordan BD, Cirio RT, Elder J. Vitamin B1 (thiamine) and dementia. Ann N Y Acad Sci 2016;1367(01):21–30

Isenberg-Grzeda E, Shen MJ, Alici Y, Wills J, Nelson C, Breitbart W. High rate of thiamine deficiency among inpatients with cancer referred for psychiatric consultation: results of a single site prevalence study. Psychooncology 2017;26(09):1384–1389

Onishi H, Ishida M, Toyama H, et al. Early detection and successful treatment of Wernicke encephalopathy in a patient with advanced carcinoma of the external genitalia during chemotherapy. Palliat Support Care 2016;14(03):302–306

Sechi G, Sechi E, Fois C, Kumar N. Advances in clinical determinants and neurological manifestations of B vitamin deficiency in adults. Nutr Rev 2016;74(05):281–300

Onishi H, Ishida M, Tanahashi I, et al. Wernicke encephalopathy without delirium in patients with cancer. Palliat Support Care 2018;16(01):118–121

Whitfield KC, Bourassa MW, Adamolekun B, et al. Thiamine deficiency disorders: diagnosis, prevalence, and a roadmap for global control programs. Ann N Y Acad Sci 2018;1430(01):3–43

Fattal-Valevski A. Thiamine (vitamin B1). J Evid Based Complementary Altern Med 2011;16:12–20

Serin HM, Arslan EA. Neurological symptoms of vitamin B12 deficiency: analysis of pediatric patients. Acta Clin Croat 2019;58(02):295–302

Reynolds EH. The neurology of folic acid deficiency. Handb Clin Neurol 2014;120:927–943

Seeman MV. Psychopathology in women and men: focus on female hormones. Am J Psychiatry 1997;154(12):1641–1647

Bartley JC, McGrath H, Abraham S. Glucose and acetate utilization by hyperplastic, alveolar nodule outgrowths and adenocarcinomas of mouse mammary gland. Cancer Res 1971;31(05):527–537